Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.

MLA

Sing, Chor‐Wing, et al. “Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.” Journal of Bone & Mineral Research, vol. 33, no. 8, Aug. 2018, pp. 1422–34. EBSCOhost, https://doi.org/10.1002/jbmr.3448.

APA

Sing, C., Wong, A. Y. S., Kiel, D. P., Cheung, E. Y. N., Lam, J. K. Y., Cheung, T. T., Chan, E. W., Kung, A. W. C., Wong, I. C. K., & Cheung, C. (2018). Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. Journal of Bone & Mineral Research, 33(8), 1422–1434. https://doi.org/10.1002/jbmr.3448

Chicago

Sing, Chor‐Wing, Angel Y. S. Wong, Douglas P. Kiel, Elaine Y. N. Cheung, Joanne K. Y. Lam, Tommy T. Cheung, Esther W. Chan, Annie W. C. Kung, Ian C. K. Wong, and Ching‐Lung Cheung. 2018. “Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.” Journal of Bone & Mineral Research 33 (8): 1422–34. doi:10.1002/jbmr.3448.